Abstract 78P
Background
EVIDENS was a prospective, non-interventional, multicenter study evaluating nivolumab in metastatic NSCLC, initiated before immunotherapy was available in first-line. This final analysis presents results at 36-months’ follow-up.
Methods
Adults with pathologically confirmed lung cancer initiating nivolumab between October 2016–November 2017 were included and followed up until December 2020. Patient characteristics were recorded at diagnosis & nivolumab initiation. Survival was evaluated with the Kaplan-Meier method & quality of life (QoL) with the EuroQol-5D-3 Level (EQ-5D-3L) questionnaire and visual analog scale (VAS).
Results
A total of 1423 patients with NSCLC (69% male, median age 66 years) were included in this analysis. At nivolumab initiation, most patients had an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–1 (83.0%), non-squamous histology (69.1%), stage IV disease (91.5%) & were current/former smokers (89.8%); 19.9% had brain metastases. Most patients (99.7%) had previously received chemotherapy; nivolumab was second line therapy in 73.5% of patients with a median treatment duration of 73.0 days. Median overall survival (OS) was 11.0 months (95%CI: 9.8–12.2) & progression-free survival (PFS) 3.0 months (95% CI: 2.6–3.2). In multivariate analyses, patients with squamous NSCLC, liver metastasis, ECOG-PS ≥2 or who never smoked had significantly higher risk of shorter OS & PFS. Age, brain metastasis, or corticosteroid therapy at nivolumab initiation had no effect on OS & PFS. The overall response rate was 12.1%; median duration of response was 13 months. Treatment-related adverse events occurred in 35.7% (any grade), 8.0% (grade 3) and 0.8% (grade 4) of patients. Patients continuously treated with nivolumab had better EQ-5D-3L VAS scores than those who discontinued.
Conclusions
EVIDENS final analysis confirm the effectiveness, safety & effect on QoL of nivolumab reported in clinical trials. They help inform clinical practice by virtue of a long-term follow-up & subgroup analyses suggesting greater benefit in certain patients. This conclusion might be explored further in the LIST study.
Clinical trial identification
NCT03382496.
Editorial acknowledgement
Tracy Harrison of Springer Healthcare Communications provided editing of the abstract prior to submission. Yaacoub Khalife of Bristol Myers Squibb France Medical Oncology Department provided editing of the abstract prior to submission.
Legal entity responsible for the study
The authors.
Funding
Bristol Myers Squibb.
Disclosure
F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, ACEA, Amgen, Eisai, Ignyta; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Pfizer, OSE Immunotherapeutics, Novartis, Sanofi Aventis, Amgen, Roche, Ipsen; Financial Interests, Personal, Invited Speaker: Gilead, Takeda; Financial Interests, Personal, Coordinating PI: Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Novartis, Takeda, Bayer, Sanofi Aventis. J.B. Auliac: Financial Interests, Personal, Speaker, Consultant, Advisor: Sanofi, Janssen, AstraZeneca, Takeda, BMS, MSD. D. Moro-Sibilot: Financial Interests, Personal, Advisory Board: Lilly, Roche, BMS, MSD, AbbVie, Becton Dickinson, Pfizer, Takeda, AstraZeneca, Boehringer Ingelheim, Novartis, GSK, Sanofi; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Institutional, Funding, IFCT clinical trials: Pfizer; Financial Interests, Institutional, Funding: Roche, AbbVie, AstraZeneca. B. Asselain: Financial Interests, Personal, Other: BMS, AstraZeneca, Pierre Fabre, Servier, Daiichi Sankyo, Gilead. C. Audigier-Valette: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, AstraZeneca, Sanofi, Janssen; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer. F. Breliier, E. Gauthier, D. Reynaud: Financial Interests, Personal, Full or part-time Employment: BMS. F. Cotté: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche; Financial Interests, Personal, Other, DMSB: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display